Global medical technology company Medtronic has announced plans to acquire SPR Therapeutics in a deal valued at approximately $650 million. The acquisition is expected to strengthen Medtronic’s position in chronic pain management by expanding its portfolio of minimally invasive and non-opioid treatment technologies.
The move reflects the growing demand for safer and more advanced alternatives to traditional pain treatment methods, particularly as healthcare systems worldwide continue searching for solutions beyond long-term opioid use.
Focus on advanced chronic pain management.
Chronic pain remains one of the largest global healthcare challenges, affecting millions of people and significantly impacting quality of life, mobility, and mental health. Healthcare experts estimate that nearly 50 million adults in the United States alone live with chronic pain conditions.
Through the acquisition, Medtronic will gain access to SPR Therapeutics’ innovative SPRINT Peripheral Nerve Stimulation system, a technology designed to provide temporary pain relief without requiring permanent implants.
The therapy uses temporary peripheral nerve stimulation to target pain signals and is designed as a short-term, 60-day treatment option for patients suffering from chronic pain conditions.
Growing Shift Toward Non-Opioid Therapies
Healthcare providers globally are increasingly moving toward non-opioid pain management solutions due to concerns surrounding opioid dependency, addiction risks, and long-term side effects.
The acquisition aligns with this broader healthcare trend by strengthening Medtronic’s capabilities in:
- Non-opioid pain management
- Minimally invasive treatment
- Neuromodulation therapies
- Early-stage pain intervention
Experts believe temporary nerve stimulation technologies can help patients access pain relief earlier in their treatment journey while potentially reducing reliance on long-term medication use.
How The Technology Works
SPR Therapeutics’ SPRINT system is an FDA-cleared peripheral nerve stimulation technology that uses thin wire-like leads placed near targeted nerves to deliver mild electrical stimulation.
Unlike many traditional pain devices, the system:
- Does not require permanent implants
- Uses a minimally invasive outpatient procedure
- Is designed for temporary 60-day therapy
- Integrates into existing clinical workflows
The goal is to interrupt pain signals and help patients achieve sustained pain relief even after the therapy period ends.
Healthcare experts view this type of technology as part of a larger shift toward personalized and less invasive pain management solutions.
Strong Clinical Performance
According to available clinical data, the SPRINT system has shown encouraging results in chronic pain treatment.
A large retrospective review involving more than 6,100 patients reported that over 71 percent of participants experienced significant pain relief or improvement in quality of life following the 60-day therapy.
The technology has been used for managing several types of pain conditions, including:
- Chronic back pain
- Post-surgical pain
- Neuropathic pain
- Musculoskeletal pain
- Post-traumatic pain
These results have contributed to growing interest in peripheral nerve stimulation therapies within the medical technology industry.
Strengthening Medtronic’s Neuromodulation Portfolio
Medtronic already operates one of the world’s largest neuromodulation businesses, offering technologies focused on spinal cord stimulation, brain stimulation, and pain management systems.
The acquisition of SPR Therapeutics is expected to further strengthen the company’s neuroscience and pain management portfolio by adding earlier-stage intervention options for chronic pain patients.
Company officials stated that the addition of temporary peripheral nerve stimulation technology will help Medtronic support patients across different stages of pain treatment with more flexible and minimally invasive options.
Rising Importance Of Neuromodulation In Healthcare
Neuromodulation therapies are becoming increasingly important in modern medicine as healthcare systems focus on:
- Precision-based treatment
- Reduced dependence on medication
- Minimally invasive interventions
- Improved quality of life for chronic disease patients
Peripheral nerve stimulation is considered one of the fastest-growing segments within the pain management technology market due to expanding clinical evidence and improving reimbursement coverage.
Industry experts expect demand for advanced pain technologies to continue rising as aging populations and chronic pain conditions increase globally.
Strategic Growth For Medtronic
The SPR Therapeutics acquisition is also part of Medtronic’s broader strategy to strengthen its core healthcare technology businesses through targeted acquisitions and innovation-focused expansion.
In recent years, the company has increased investments in areas such as:
- Robotics-assisted surgery
- AI-enabled healthcare systems
- Cardiovascular devices
- Neuroscience and pain management technologies
Healthcare analysts believe the latest acquisition reflects Medtronic’s long-term focus on expanding technology-driven treatment solutions across major healthcare segments.
Challenges And Future Outlook
While peripheral nerve stimulation technologies show strong potential, experts note that wider adoption will depend on factors such as:
- Physician training and awareness
- Long-term clinical outcome data
- Insurance reimbursement coverage
- Accessibility and affordability for patients
However, the growing need for safer and less invasive chronic pain therapies is expected to continue driving innovation in this segment.
The transaction is expected to close during the first half of Medtronic’s fiscal year 2027, subject to regulatory approvals and standard closing conditions.
Conclusion
Medtronic’s planned acquisition of SPR Therapeutics marks another major step in the evolution of modern pain management technologies. By adding temporary peripheral nerve stimulation solutions to its portfolio, the company aims to expand access to minimally invasive and non-opioid chronic pain treatments.
As healthcare systems continue prioritizing safer, technology-driven pain management solutions, innovations in neuromodulation and nerve stimulation therapies are expected to play an increasingly important role in improving patient care and quality of life worldwide.
